Search | Clinical Trials Finder

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: Evolocumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions: Placebo, Obicetrapib; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 2,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 69
States / cities: Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more

Conditions: Familial Hypercholesterolemia
Interventions: FH diagnosis program, Implementation strategy package: Develop and implement tools for quality monitoring, Implementation strategy package: Develop educational materials, Implementation strategy package: Conduct educational outreach visits, Implementation strategy package: Intervene with clinicians and patients to enhance, Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions, Implementation strategy package: Audit and provide feedback, Implementation strategy package: Stage implementation scale up; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 26 Years and older
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Multiple Locations, Pennsylvania

Conditions: Atherosclerosis, Coronary Artery Disease
Interventions: lovastatin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 21 Years to 67 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1985 – 1992
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Heterozygous Familial Hypercholesterolemia
Interventions: Evolocumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 12
States / cities: Farmington, Connecticut • Wilmington, Delaware • Iowa City, Iowa + 9 more

Conditions: Type 2 Diabetes, Hypertension, Hyperlipidemia, Health-related Social Problems
Interventions: Multi-level HRSN initiative; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4,809 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions: ALN-PCSSC, Normal Saline; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Hypercholesteremia
Interventions: Gemcabene; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 17 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Diabetes Mellitus Type 2
Interventions: Internet Intervention, Control; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Not listed
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama

Conditions: Familial Hypercholesterolemia
Interventions: Implitapide; Drug
Lead sponsor: Medical Research Laboratories International; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more

Conditions: Myalgia, Hypercholesterolemia, Hyperlipidemia
Interventions: PPD10558, Atorvastatin, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 67
States / cities: Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more

Conditions: ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
Interventions: Inclisiran Sodium; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 141
States / cities: Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 109 more

Conditions: Hypercholesterolemia
Interventions: Not listed
Lead sponsor: The Familial Hypercholesterolemia Foundation; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Prediabetes, Obesity
Interventions: Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 30 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Familial Hypercholesterolemia - Homozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri

Conditions: Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions: mipomersen sodium; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 5
States / cities: Chicago, Illinois • Auburn, Maine • Biddeford, Maine + 2 more

Conditions: Homozygous Familial Hypercholesterolemia (HoFH)
Interventions: AAV directed hLDLR gene therapy; Genetic
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 5
States / cities: Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more

Conditions: Heterozygous Familial Hypercholesterolemia (HeFH)
Interventions: Enlicitide Decanoate, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 6
States / cities: Wilmington, Delaware • Washington D.C., District of Columbia • Boca Raton, Florida + 3 more

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Exenatide, Normal Saline; Drug · Other
Lead sponsor: Carl T. Hayden VA Medical Center; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Familial Hypercholesterolemia - Heterozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions: bempedoic acid, placebo; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 52
States / cities: Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: lerodalcibep, evolocumab; Drug
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 10 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Evanston, Illinois • Cincinnati, Ohio

Conditions: Familial Hypercholesterolemia
Interventions: atorvastatin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 6 Years to 15 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 3 more

Search by objective public record fields.

Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)

MARS - Monitored Atherosclerosis Regression Study

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

Evaluating the Effectiveness of a Multi-level Health-Related Social Needs Initiative

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)

Internet Intervention to Improve Rural Diabetes Care

Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

Study of Awareness and Detection of Familial Hypercholesterolemia

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

Atorvastatin Three Year Pediatric Study